Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.
about
Antidepressants for smoking cessationAntidepressants for smoking cessationA high-coverage genome sequence from an archaic Denisovan individualA review of pharmacogenetic studies of substance-related disordersConvergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence.Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.An integrated phenomic approach to multivariate allelic association.Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses.Sex heterogeneity in pharmacogenetic smoking cessation clinical trialsNeurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch.Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans.Gene-environment interactions across development: Exploring DRD2 genotype and prenatal smoking effects on self-regulation.Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome.Pharmacogenetics of nicotine addiction: role of dopaminePharmacogenetics of antidepressant response.Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Genetic linkage findings for DSM-IV nicotine withdrawal in two populations.Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2)PharmGKB summary: dopamine receptor D2Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trialsMolecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.Biomarkers to optimize the treatment of nicotine dependence.Genetic factors modulating the response to stimulant drugs in humans.Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk scoreMolecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical UtilityPharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.Genetic analysis of polymorphisms in dopamine receptor and transporter genes for association with smoking among cancer patientsNicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.Neuroimaging, genetics and the treatment of nicotine addictionThe CHRNA3 rs578776 Variant is Associated with an Intrinsic Reward Sensitivity Deficit in Smokers.Genetic variation in the dopamine pathway and smoking cessation.Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.DRD2-related TaqIA polymorphism modulates motivation to smoke.Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Genetics of dopamine receptors and drug addiction.CNS genes implicated in relapseAssociation of a common genetic variant within ANKK1 with six-month cognitive performance after traumatic brain injuryThe ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.
P2860
Q24201167-B0D03E38-EFB3-4AE8-ABB0-6AE18DF510FCQ24246426-02E3A7E9-CE8B-457C-9962-FA35C5C4D7F6Q24595378-A7A35B32-BC4B-46FA-AE74-35FB37CA04D4Q27312296-57E779BC-8567-4743-8708-12B43785EB44Q30434359-9E007E92-C1AC-4501-BC68-74BD0CAFF14FQ30445824-3A0F5422-9DD3-4BA4-A7C2-BF089F1B3B28Q30492795-0DB24D06-120E-439D-88DF-93A8E99A6E36Q31159653-C863030C-6D01-408B-A63C-15DFE7C5D674Q33605769-D0F90258-F2ED-429F-9EEF-B656C95C9873Q33609822-99622C38-D1CD-4C36-883F-D384628AF702Q33671613-91E6B784-D98E-4E8A-AA82-72E7D8661F58Q33791947-65CB9D85-2387-4C3A-9A14-C6C393544B72Q33893086-6AA1D263-019B-4951-BF00-E7E3FBBDE302Q34132214-6D8FC5A6-2498-431B-93A0-6E8526930FFBQ34155796-D28DAAD3-4743-447D-AFC3-9411278F9444Q34311649-F175539B-6365-4467-B37D-773BB01358AEQ34373128-45C0E049-F5AA-42A3-85AD-CA3F6164DC99Q34772521-455EB26C-4A6A-48FA-BA26-1C40B5A6A726Q34970259-4799CECD-CCFF-4C4E-9D8E-D5A9C2A3014EQ35022995-58834650-4A38-4A54-994D-BE3F4ED899C2Q35684332-1CA593C4-75CA-4A5C-AE50-07A9E562779EQ35773685-D3739763-1B7C-4948-85B8-E33DD15EB70DQ36071808-BDA2AFFC-F992-48FC-9E95-5484159483B1Q36286817-F152B060-E3ED-44E1-A183-E501C1F2668DQ36482731-539F89AE-5EAD-44D9-A6D1-8F4ADCBABBC3Q36727883-510C9F57-E4A5-4207-A893-BCBD23BFBB71Q36829619-D749693E-CC20-45F9-A6BD-0D84409B9CA2Q36851620-9386069E-F8C3-46D7-8B23-20B63D396FEFQ37010016-3E99D305-5475-4B2D-BF2F-754140127F10Q37189885-74546604-22DD-49C4-9F1C-4A4ED9F3830CQ37264547-044B2933-A261-4507-AD8A-ABA841D87308Q37280300-4C523115-3C1D-48C2-A61E-1AEDE7C97E43Q37325773-B93FDD26-F840-48ED-9E5C-C796E216424BQ37389482-E7F54154-E667-4679-9144-2A6C79C5E867Q37848476-653C2CEE-BBB3-4F2F-A15B-23D3523B4761Q37986616-22D5B386-87C7-4E71-8547-924DA73B395FQ38448419-3CABFD55-F88D-4A61-815C-2A2CAD7DCD75Q39045957-CFA1139D-DD29-4FD2-B544-E43172ED2788Q42477109-9682E718-864D-4210-8397-0935AA575882Q48015634-F5641AB7-F7A9-42B7-96F8-C006467C3906
P2860
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Bupropion efficacy for smoking ...... data from two clinical trials.
@ast
Bupropion efficacy for smoking ...... data from two clinical trials.
@en
type
label
Bupropion efficacy for smoking ...... data from two clinical trials.
@ast
Bupropion efficacy for smoking ...... data from two clinical trials.
@en
prefLabel
Bupropion efficacy for smoking ...... data from two clinical trials.
@ast
Bupropion efficacy for smoking ...... data from two clinical trials.
@en
P2093
P2860
P50
P1476
Bupropion efficacy for smoking ...... data from two clinical trials.
@en
P2093
David R Strong
Eden A Evins
Elizabeth E Lloyd-Richardson
Paul E Wileyto
Peter G Shields
Richard A Brown
P2860
P304
P356
10.1080/14622200701705027
P577
2007-12-01T00:00:00Z